Home » Newsletters » BioWorld Science

BioWorld Science

May 30, 2019

View Archived Issues

CD47 prevents gene therapy from being eaten

Gallbladder cancer murine models developed from organoid cell lines

Circulating elafin as potential new biomarker of prediabetic condition

Urinary Cyr61 and TFF3 as promising new biomarkers in patients with colorectal cancer

Akero Therapeutics initiates phase IIa study of AKR-001 for the treatment of NASH

Expansion Therapeutics initiates phase I trial of ERX-963 in adults with DM1

Polyphor, University of Zurich awarded grant to develop new class of LPS-inhibiting antibiotics

SNX29 variation plays a role in vasodilator therapy response in PAH

Strep genome research expedites vaccine development

TRPV1 as a novel target in gastric cancer therapy

Gut-derived live bacterial strains found to modulate neuroinflammation and neurodegeneration in PD

Medshine Discovery divulges mTORC1 and mTORC2 inhibitors

Sumitomo Dainippon Pharma patents TLR7 antagonists

Xeomin approved in E.U. for treatment of chronic sialorrhea in adults

German researchers present new adenosine A2A receptor ligands

Metacrine reports phase Ib interim data on FXR agonist MET-409 in NASH

Jubilant Biosys describes PD-1/PD-L1 interaction inhibitors

Phase III KALM-1 study of Korsuva in hemodialysis patients with pruritus meets primary endpoint

Merck & Co. discovers IDO1 inhibitors

Michael J. Fox Foundation awards Casma Therapeutics grant to advance PD drug development

NRF2 gene polymorphism tied to emphysema development in smokers

Amicus and University of Pennsylvania expand gene therapy collaboration

AdCh3NSmut1/MVA-NSmut did not protect against HCV infection in phase I/II trial

Mereo reports 6-month open-label data from phase IIb study of BPS-804 in osteogenesis imperfecta

Phase III QUARTZ study of QMF-149 in inadequately controlled asthma meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...